{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:28:58Z","timestamp":1793424538681,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014181","name":"Extremadura Government","doi-asserted-by":"publisher","award":["GR24027"],"award-info":[{"award-number":["GR24027"]}],"id":[{"id":"10.13039\/501100014181","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/00181"],"award-info":[{"award-number":["PI22\/00181"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.isci.2025.114143","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:17:07Z","timestamp":1763659027000},"page":"114143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combined concentrations and genetic variability of fibroblast growth factors predict cardiovascular risk in renal patients"],"prefix":"10.1016","volume":"28","author":[{"given":"Laura","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mart\u00ed-Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mota-Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Chicharro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Cancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoraida","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fern\u00e1ndez-Araque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bandr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s Roberto","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0524-9767","authenticated-orcid":false,"given":"Guillermo","family":"Gervasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.114143_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/ijms22010043","article-title":"New Potential Biomarkers for Chronic Kidney Disease Management-A Review of the Literature","volume":"22","author":"Lousa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114143_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ndt\/gfy126","article-title":"Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications?","volume":"34","author":"Kuro-O","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.isci.2025.114143_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14737159.2020.1780918","article-title":"Endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease","volume":"20","author":"Kondo","year":"2020","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.isci.2025.114143_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2169\/internalmedicine.3597-19","article-title":"Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients","volume":"59","author":"Yamamoto","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.isci.2025.114143_bib5","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.asjsur.2021.12.064","article-title":"Change of cardiovascular risk associated serologic biomarkers after gastric bypass: A comparison of diabetic and non-diabetic Asian patients","volume":"45","author":"Wei","year":"2022","journal-title":"Asian J. Surg."},{"key":"10.1016\/j.isci.2025.114143_bib6","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/CM9.0000000000001574","article-title":"Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes","volume":"134","author":"Hu","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.isci.2025.114143_bib7","doi-asserted-by":"crossref","first-page":"iv212","DOI":"10.1093\/ndt\/gft337","article-title":"Impaired postprandial fibroblast growth factor (FGF)-19 response in patients with stage 5 chronic kidney diseases is ameliorated following antioxidative therapy","volume":"28","author":"Li","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.isci.2025.114143_bib8","first-page":"1207","article-title":"Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21. Kidney Blood Press","volume":"44","author":"Marchelek-Mysliwiec","year":"2019","journal-title":"Res."},{"key":"10.1016\/j.isci.2025.114143_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/s-0029-1243249","article-title":"Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters","volume":"42","author":"Reiche","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.isci.2025.114143_bib10","article-title":"High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.isci.2025.114143_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/dc08-1054","article-title":"Serum levels of the adipokine FGF21 depend on renal function","volume":"32","author":"Stein","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.isci.2025.114143_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114143_bib13","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2025.114143_bib14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114143_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312838","article-title":"Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors","volume":"25","author":"Carullo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114143_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9387358","article-title":"Genetic Variants Flanking the FGF21 Gene Were Associated with Renal Function in Chinese Patients with Type 2 Diabetes","volume":"2019","author":"Yu","year":"2019","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.isci.2025.114143_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000496060","article-title":"Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis","volume":"49","author":"Schwantes-An","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.isci.2025.114143_bib18","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s11255-019-02193-3","article-title":"The predictive value of Klotho polymorphism, in addition to classical markers of CKD-MBD, for left ventricular hypertrophy in haemodialysis patients","volume":"51","author":"Apostolovic","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.isci.2025.114143_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.12688\/f1000research.22989.1","article-title":"Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a systematic review and meta-analysis","volume":"9","author":"Gunawan","year":"2020","journal-title":"F1000Res."},{"key":"10.1016\/j.isci.2025.114143_bib20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2025.114143_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/biom13101481","article-title":"A Combined Biomarker That Includes Plasma Fibroblast Growth Factor 23, Erythropoietin, and Klotho Predicts Short- and Long-Term Morbimortality and Development of Chronic Kidney Disease in Critical Care Patients with Sepsis: A Prospective Cohort","volume":"13","author":"Toro","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.isci.2025.114143_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11110647","article-title":"FGF23 and Phosphate-Cardiovascular Toxins in CKD","volume":"11","author":"Vogt","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.isci.2025.114143_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fendo.2018.00351","article-title":"FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?","volume":"9","author":"Stohr","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114143_bib24","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/ndt\/gfs259","article-title":"FGF-23: the rise of a novel cardiovascular risk marker in CKD","volume":"27","author":"Heine","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.isci.2025.114143_bib25","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1681\/ASN.2017121334","article-title":"Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis","volume":"29","author":"Marthi","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2025.114143_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)","volume":"60","author":"Ix","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.isci.2025.114143_bib27","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1152\/ajpendo.00264.2014","article-title":"FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability","volume":"307","author":"Silswal","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114143_bib28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jchf.2015.05.012","article-title":"Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure","volume":"3","author":"Wohlfahrt","year":"2015","journal-title":"JACC. Heart Fail."},{"key":"10.1016\/j.isci.2025.114143_bib29","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00198-011-1838-0","article-title":"FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages","volume":"23","author":"Desjardins","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.isci.2025.114143_bib30","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00359.2016","article-title":"Ironing out the cross talk between FGF23 and inflammation","volume":"312","author":"David","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.isci.2025.114143_bib31","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114143_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072345","article-title":"Serum levels of fibroblast growth factor 19 are inversely associated with coronary artery disease in chinese individuals","volume":"8","author":"Hao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114143_bib33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fendo.2020.00282","article-title":"Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114143_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/a-2549-6889","article-title":"Association of FGF21 with Metabolic and Cardiovascular Diseases: A Mendelian Randomization Analysis","volume":"133","author":"He","year":"2025","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.isci.2025.114143_bib35","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12235","article-title":"Elevated serum FGF21 predicts the major adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention","volume":"9","author":"Gu","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.isci.2025.114143_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.metabol.2018.11.006","article-title":"High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)","volume":"93","author":"Ong","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2025.114143_bib37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1210\/me.2015-1155","article-title":"Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases","volume":"29","author":"Zhang","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.isci.2025.114143_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155616","article-title":"Renoprotective effects of genetically proxied fibroblast growth factor 21: Mendelian randomization, proteome-wide and metabolome-wide association study","volume":"145","author":"Giontella","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2025.114143_bib39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1210\/er.2018-00134","article-title":"Fibroblast Growth Factor 15\/19: From Basic Functions to Therapeutic Perspectives","volume":"39","author":"Somm","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.isci.2025.114143_bib40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1597\/11-132","article-title":"The FGF and FGFR Gene Family and Risk of Cleft Lip With or Without Cleft Palate","volume":"50","author":"Wang","year":"2013","journal-title":"Cleft Palate Craniofac. J."},{"key":"10.1016\/j.isci.2025.114143_bib47","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1089\/dna.2011.1552","article-title":"Fibroblast growth factor receptor 4 polymorphisms and susceptibility to coronary artery disease","volume":"31","author":"Ma","year":"2012","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.isci.2025.114143_bib48","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1177\/030006051204000509","article-title":"Association between fibroblast growth factor receptor 4 Gly388Arg polymorphism and ischaemic stroke","volume":"40","author":"Zhang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.isci.2025.114143_bib49","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1159\/000519274","article-title":"FGFR4 and Klotho Polymorphisms Are Not Associated with Cardiovascular Outcomes in Chronic Kidney Disease","volume":"52","author":"Sellier","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.isci.2025.114143_bib41","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJMra2308577","article-title":"Genetics of Chronic Kidney Disease","volume":"391","author":"Vivante","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114143_bib42","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.3390\/biomedicines11102775","article-title":"Prognostic Significance of Amino Acid and Biogenic Amines Profiling in Chronic Kidney Disease","volume":"11","author":"Gervasini","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2025.114143_bib43","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s41598-022-27343-z","article-title":"Influence of variability in the cyclooxygenase pathway on cardiovascular outcomes of nephrosclerosis patients","volume":"13","author":"Gonzalez","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114143_bib44","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cjco.2025.02.016","article-title":"Development and Validation of Models to Predict Major Adverse Cardiovascular Events in Chronic Kidney Disease","volume":"7","author":"Tangri","year":"2025","journal-title":"CJC Open"},{"key":"10.1016\/j.isci.2025.114143_bib45","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114143_bib46","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1159\/000519274","article-title":"FGFR4 and Klotho Polymorphisms Are Not Associated with Cardiovascular Outcomes in Chronic Kidney Disease","volume":"52","author":"Sellier","year":"2021","journal-title":"Am. J. Nephrol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225024046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225024046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:53:23Z","timestamp":1783475603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225024046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2589004225024046"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.114143","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined concentrations and genetic variability of fibroblast growth factors predict cardiovascular risk in renal patients","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.114143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114143"}}